Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

AUCATZYL ® net product revenue of $23.3 million* for Q4 2025 and $74.3 million* for full year 2025; UK launch underway following NICE evaluation

Mar. 27, 2026 at 11:57am

Got story updates? Submit your updates here. ›

Autolus Therapeutics, a commercial-stage biopharmaceutical company, announced its operational and financial results for the fourth quarter and full year ended December 31, 2025. The company reported net product revenue of $23.3 million* for Q4 2025 and $74.3 million* for the full year 2025, driven by U.S. sales of its therapy AUCATZYL ®. Following a successful NICE evaluation, AUCATZYL launched in the UK in January 2026. The company also provided updates on its pipeline, including pivotal trials for obe-cel in pediatric r/r B-ALL and lupus nephritis, as well as the initiation of a Phase 1 trial in progressive multiple sclerosis.

Why it matters

Autolus Therapeutics is a leading developer of next-generation T cell therapies, and the commercial launch of AUCATZYL in the U.S. and now the UK represents an important milestone for the company. The positive real-world data on AUCATZYL's safety and efficacy profile, as well as the company's progress in expanding obe-cel into new indications, suggest Autolus is well-positioned to drive further growth and adoption of its therapies.

The details

Autolus reported net product revenue of $23.3 million* for Q4 2025 and $74.3 million* for the full year 2025, driven by U.S. sales of AUCATZYL. The company also launched AUCATZYL in the UK in January 2026 following a successful NICE evaluation. Real-world data from the ROCCA consortium showed consistency in both safety and efficacy of AUCATZYL compared to clinical trial results. Autolus also provided updates on its pipeline, including positive preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric r/r B-ALL, the initiation of the LUMINA Phase 2 trial of obe-cel in lupus nephritis, and the start of the BOBCAT Phase 1 trial evaluating obe-cel in progressive multiple sclerosis.

  • In Q4 2025, Autolus reported net product revenue of $23.3 million* for AUCATZYL.
  • For the full year 2025, Autolus reported net product revenue of $74.3 million* for AUCATZYL.
  • AUCATZYL launched in the UK in January 2026 following a successful NICE evaluation.
  • Data from the ROCCA consortium on real-world use of AUCATZYL was presented at ASH in December 2025 and TANDEM in February 2026.
  • The first patient in the BOBCAT trial evaluating obe-cel in progressive MS was dosed in October 2025.

The players

Autolus Therapeutics plc

A commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease.

AUCATZYL ®

A B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell therapy developed by Autolus and approved for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

ROCCA Consortium

A real-world outcomes collaborative that collected data on approximately 60% of U.S. commercial patients treated with AUCATZYL.

Dr. Christian Itin

Chief Executive Officer of Autolus Therapeutics.

obe-cel

The generic name for Autolus' CD19 CAR T cell therapy, also known as obecabtagene autoleucel.

Got photos? Submit your photos here. ›

What they’re saying

“Autolus had a strong first year of launch of AUCATZYL in the US building a market leading position in adult patients with relapsed or refractory B-ALL and demonstrating strong commercial execution, including reliable, high-quality product delivery with consistent turn-around time.”

— Dr. Christian Itin, Chief Executive Officer

“Recently reported data confirm a high level of clinical activity without inducing high grade CRS and only 3% of patients experiencing high grade ICANS. We expect this positive customer experience will be a key driver for the future growth of AUCATZYL.”

— Dr. Christian Itin, Chief Executive Officer

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.